AX-2025-019211
Tirzepatide · 60 mg declared · SinoPep Biotechnology (Changzhou) Co., Ltd. · lot SNP-2502-X4903
- Report ID
- AX-2025-019211
- Compound
- Tirzepatide
- Compound class
- Incretin analogues and co-agonists
- Supplier
- SinoPep — SinoPep Biotechnology (Changzhou) Co., Ltd.
- Batch / lot
- SNP-2502-X4903
- Declared label claim
- 60mg
- Laboratory
- PeptideMeter
- Assay date
- 08 May 2025
- Submitted
- 31 May 2025
- Quarter
- 2025-Q2
- Submitter
- l.pereira
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 28 min gradient, 214 nm | 98.42 | % area | ≥ 97.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 1.58 | % area | ≤ 3.0 | PASS |
| Largest single impurity | RP-HPLC — trifluoroacetyl adduct (+96 Da) | 1.10 | % area | ≤ 1.00 | FAIL |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 4810.4103 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 4810.4074 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -0.6 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 85.66 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 84.31 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 76.22 | mg | 60 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 64.261 | mg | 60 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 107.1 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 6.41 | % | ≤ 8.0 | PASS |
| Counter-ion (TFA) | anion-exchange ion chromatography | 7.43 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.50 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | Off-white lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 3.22 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 28 min gradient | 18.62 | min | 18.64 ± 0.45 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.18 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 66,170 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs des-Aib2 analogue | 1.10 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Tirzepatide — main peak | 18.62 | 4,783,517 | 98.42 | — |
| 2 | trifluoroacetyl adduct (+96 Da) | 19.49 | 53,463 | 1.10 | +95.982 |
| 3 | C20 diacid mono-amide | 20.13 | 11,665 | 0.24 | +0.984 |
| 4 | des-Aib2 analogue | 18.29 | 6,318 | 0.13 | -85.053 |
| 5 | truncated (3-39) | 17.24 | 2,916 | 0.06 | -222.112 |
| 6 | des-Gly deletion (−57 Da) | 18.05 | 1,458 | 0.03 | -57.021 |
| 7 | tirzepatide dimer | 22.33 | 972 | 0.02 | +4810.410 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 4810.4103 Da, computed from C225H348N48O68. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 7+ | 688.2087 | 688.2083 | -0.0004 | 8.8 |
| 6+ | 802.7423 | 802.7418 | -0.0005 | 56.2 |
| 5+ | 963.0893 | 963.0888 | -0.0005 | 100.0 |
| 4+ | 1203.6099 | 1203.6091 | -0.0008 | 59.6 |
| 3+ | 1604.4774 | 1604.4764 | -0.0010 | 8.6 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 6.41 |
| Counter-ion (TFA) | ion chromatography | 7.43 |
| Residual solvent + inorganic residue | estimated | 0.50 |
| Total peptide content | by difference | 85.66 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.13 | 98.42 | divergence +0.50 pp vs batch median |
| Total impurities (% area) | 0.87 | 1.58 | |
| Largest single impurity (% area) | 0.52 | 1.10 | |
| Water (%) | not stated | 6.41 | |
| Counter-ion (%) | not stated | 7.43 | |
| Peptide content (%w/w) | 91.7 | 85.66 | |
| Endotoxin (EU/mg) | 0.39 | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (2–8 °C, 5 d) → laboratory (courier, ambient, 4 d) → assay.
- Assay date
- 08 May 2025
- Submitted to the index
- 31 May 2025
- Laboratory
- PeptideMeter, Tallinn, Estonia
- Method basis
- 28 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations 2
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot SNP-2502-X4903 n=10
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-019203 | SNP-2502-X4903 | PeptideMeter | 2025-Q2 | 98.95 | 6.25 | 92.2 | Buyer-sourced | 0 | PASS |
| AX-2025-019204 | SNP-2502-X4903 | Medutest | 2025-Q2 | 99.02 | 6.19 | 93.3 | Buyer-sourced | 0 | PASS |
| AX-2025-019205 | SNP-2502-X4903 | Medutest | 2025-Q2 | 98.40 | 5.85 | 90.2 | Buyer-sourced | 0 | PASS |
| AX-2025-019206 | SNP-2502-X4903 | PeptideMeter | 2025-Q2 | 98.51 | 6.80 | 100.5 | Buyer-sourced | 0 | PASS |
| AX-2025-019207 | SNP-2502-X4903 | Janoshik | 2025-Q2 | 98.61 | 5.72 | 100.5 | Buyer-sourced | 0 | PASS |
| AX-2025-019208 | SNP-2502-X4903 | Janoshik | 2025-Q2 | 98.65 | 6.20 | — | Buyer-sourced | 0 | PASS |
| AX-2025-019209 | SNP-2502-X4903 | Janoshik | 2025-Q2 | 98.66 | 6.83 | — | Buyer-sourced | 1 | FAIL |
| AX-2025-019210 | SNP-2502-X4903 | VendorInvestigate | 2025-Q2 | 98.46 | 6.13 | 98.1 | Buyer-sourced | 0 | PASS |
| AX-2025-019212 | SNP-2502-X4903 | Janoshik | 2025-Q2 | 98.95 | 6.85 | 101.4 | Buyer-sourced | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043288 | CPC | CPC-2607-L1516 | Janoshik | 2026-Q3 | 96.89 | 5.11 | 101.1 | Laboratory-retained | 0 | FAIL |
| AX-2026-041610 | FGP | FGP-2603-L7753 | Janoshik | 2026-Q3 | 98.81 | 2.45 | 101.0 | Buyer-sourced | 0 | PASS |
| AX-2026-041974 | AMB | AMB-2603-C5112 | Nordanalyt | 2026-Q3 | 98.20 | 3.41 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041975 | AMB | AMB-2603-C5112 | Medutest | 2026-Q3 | 97.88 | 3.45 | 106.9 | Laboratory-retained | 0 | PASS |
| AX-2026-041609 | FGP | FGP-2603-L7753 | Janoshik | 2026-Q3 | 98.52 | 2.00 | 98.0 | Buyer-sourced | 0 | PASS |
| AX-2026-041978 | AMB | AMB-2603-C5112 | Janoshik | 2026-Q3 | 97.94 | 3.57 | 103.0 | Buyer-sourced | 0 | PASS |
| AX-2026-041982 | AMB | AMB-2603-C5112 | Janoshik | 2026-Q3 | 97.60 | 4.46 | — | Buyer-sourced | 0 | PASS |
| AX-2026-043286 | CPC | CPC-2607-L1516 | Kestrel | 2026-Q3 | 98.20 | 4.56 | — | Buyer-sourced | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041867 | CJC-1295 with DAC | SNP-2607-C3886 | Janoshik | 2026-Q3 | 99.24 | 5.12 | — | Laboratory-retained | 1 | FAIL |
| AX-2026-041913 | Ipamorelin | SNP-2606-L4478 | PeptideMeter | 2026-Q3 | 98.88 | 5.28 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-041914 | Ipamorelin | SNP-2606-L4478 | Janoshik | 2026-Q3 | 99.14 | 5.49 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041909 | Ipamorelin | SNP-2606-L4478 | PeptideMeter | 2026-Q3 | 99.00 | 5.48 | 89.5 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041895 | Ipamorelin | SNP-2602-B3833 | Janoshik | 2026-Q3 | 99.93 | 4.72 | 105.9 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041930 | IGF-1 LR3 | SNP-2606-D4620 | Medutest | 2026-Q3 | 98.54 | 5.37 | 93.8 | Buyer-sourced | 0 | PASS |
| AX-2026-041898 | Ipamorelin | SNP-2602-B3833 | Nordanalyt | 2026-Q3 | 99.93 | 4.54 | 96.0 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041931 | IGF-1 LR3 | SNP-2606-D4620 | PeptideMeter | 2026-Q3 | 97.93 | 5.19 | 93.4 | Buyer-sourced | 0 | PASS |